HCA
NKTR icon

Harbor Capital Advisors’s Nektar Therapeutics NKTR Stock Holding History

Harbor Capital Advisors’s Portfolio NKTR Stock Details NKTR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q4 		– Sell
-3,318
Closed -$29.6K – 445
2023
Q3 		$29.6K Sell
3,318
-2,202
-40% -$21.2K 0.01% 443
2023
Q2 		$47.6K Buy
+5,520
New +$58.9K 0.01% 498

Other funds holding NKTR

DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
MAM
Monaco Asset Management Monaco $542M AUM 54.4% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
GCP
GSA Capital Partners London, United Kingdom $1.61B AUM 28.28% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

Harbor Capital Advisors's NKTR Position: Q4 2023 in Review

Harbor Capital Advisors sold out of Nektar Therapeutics (NKTR) in Q4 2023, closing a stake of 3,318 shares — an estimated $29.6K sold.

Harbor Capital Advisors first reported a position in NKTR in Q2 2023 and held it in 2 quarters. The position peaked at $47.6K in Q2 2023. 125 funds tracked by Wall St. Rank hold NKTR as of Q4 2023.

  • Harbor Capital Advisors reported no remaining Nektar Therapeutics position as of Q4 2023 after selling out during the quarter.
  • Harbor Capital Advisors sold 3,318 Nektar Therapeutics shares in Q4 2023, an estimated $29.6K.
  • Harbor Capital Advisors first reported a position in Nektar Therapeutics in Q2 2023 and held it in 2 quarters.
  • Harbor Capital Advisors's Nektar Therapeutics position peaked at $47.6K in Q2 2023.
  • 125 funds tracked by Wall St. Rank held Nektar Therapeutics as of Q4 2023.

Based on Harbor Capital Advisors's 13F filing for Q4 2023, filed 8 Jan 2024.